Osteopontin is overexpressed in colorectal carcinoma and is correlated with P53 by immunohistochemistry

Experimental and Therapeutic Medicine

Volumn 3, Issue 4, 2012, Pages 621-624

  Li, Jing ^a   Yang, Guang Zhi ^a   Zhu, Zi Man ^b   Zhou, Zhi Yong ^c   Li, Lin ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b 304TH HOSPITAL   (China)

^c 306 HOSPITAL OF PLA   (China)

Author keywords

Colorectal carcinoma; Immunohistochemistry; Osteopontin; P53

Indexed keywords

KI 67 ANTIGEN; OSTEOPONTIN; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; COLORECTAL CARCINOMA; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REGULATORY MECHANISM; TUMOR GROWTH;

EID: 84863053509     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.465     Document Type: Article

References (25)

1. Denhardt DT and Noda M: Osteopontin expression and function: role in bone remodeling. J Cell Biochem Suppl 30-31: 92-102, 1998.
2. Denhardt DT and Guo X: Osteopontin: a protein with diverse functions. FASEB J 7: 1475-1482, 1993.
3. Lund SA, Giachelli CM and Scatena M: The role of osteopontin in inflammatory processes. J Cell Commun Signal 3: 311-322, 2009.
4. Patani N, Jouhra F, Jiang W and Mokbel K: Osteopontin expression profiles predict pathological and clinical outcome in breast cancer. Anticancer Res 28: 4105-4110, 2008.
5. Higashiyama M, Ito T, Tanaka E and Shimada Y: Prognostic significance of osteopontin expression in human gastric carcinoma. Ann Surg Oncol 14: 3419-3127, 2007.
6. Weber GF, Lett GS and Haubein NC: Osteopontin is a marker for cancer aggressiveness and patient survival. Br J Cancer 103: 861-869, 2010.
7. Korita PV, Wakai T, Shirai Y, Matsuda Y, Sakata J, Cui X, Ajioka Y and Hatakeyama K: Overexpression of osteopontin independently correlates with vascular invasion and poor prognosis in patients with hepatocellular carcinoma. Hum Pathol 39: 1777-1783, 2008.
8. Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF and Yeatman TJ: Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 10: 184-190, 2004.
9. Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, Cantor A, Coppola D and Yeatman TJ: Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 94: 513-521, 2002.
10. Rohde F, Rimkus C, Friederichs J, Rosenberg R, Marthen C, Doll D, Holzmann B, Siewert JR and Janssen KP: Expression of osteopontin, a target gene of de-regulated Wnt signaling, predicts survival in colon cancer. Int J Cancer 21: 1717-1723, 2007.
11. Allan AL, George R, Vantyghem SA, Lee MW, Hodgson NC, Engel CJ, Holliday RL, Girvan DP, Scott LA, Postenka CO, et al: Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer. Am J Pathol 169: 233-246, 2006.
12. Carlinfante G, Vassiliou D, Svensson O, Wendel M, Heinegård D and Andersson G: Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma. Clin Exp Metastasis 20: 437-444, 2003.
13. Irby RB, McCarthy SM and Yeatman TJ: Osteopontin regulates multiple functions contributing to human colon cancer development and progression. Clin Exp Metastasis 21: 515-523, 2004.
14. Wai PY and Kuo PC: Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev 27: 103-118, 2008.
15. Leali D, Moroni E, Bussolino F and Presta M: Osteopontin overexpression inhibits in vitro re-endothelialization via integrin engagement. J Biol Chem 282: 19676-19684, 2007.
16. Anborgh PH, Mutrie JC, Tuck AB and Chambers AF: Role of the metastasis-promoting protein osteopontin in the tumour microenvironment. J Cell Mol Med 14: 2037-2044, 2010.
17. Hsu KH, Tsai HW, Lin PW, Hsu YS, Shan YS and Lu PJ: Osteopontin expression is an independent adverse prognostic factor in resectable gastrointestinal stromal tumor and its interaction with CD44 promotes tumor proliferation. Ann Surg Oncol 17: 3043-3052, 2010.
18. Dai J, Peng L, Fan K, Wang H, Wei R, Ji G, Cai J, Lu B, Li B, Zhang D, Kang Y, Tan M, Qian W and Guo Y: Osteopontin induces angiogenesis through activation of PI3K/AKT and ERK1/2 in endothelial cells. Oncogene 28: 3412-3422, 2009.
19. Fong YC, Liu SC, Huang CY, Li TM, Hsu SF, Kao ST, Tsai FJ, Chen WC, Chen CY and Tang CH: Osteopontin increases lung cancer cells migration via activation of the alphavbeta3 integrin/FAK/Akt and NF-kappaB-dependent pathway. Lung Cancer 64: 263-270, 2009.
20. Tuck AB, Hota C and Chambers AF: Osteopontin (OPN)-induced increase in human mammary epithelial cell invasiveness is urokinase (uPA)-dependent. Breast Cancer Res Treat 70: 197-204, 2001.
21. Hijiya N, Setoguchi M, Matsuura K, Higuchi Y, Akizuki S and Yamamoto S: Cloning and characterization of the human osteopontin gene and its promoter. Biochem J 303: 255-262, 1994.
22. Morimoto I, Sasaki Y, Ishida S, Imai K and Tokino T: Identification of the osteopontin gene as a direct target of TP53. Genes Chromosomes Cancer 33: 270-278, 2002.
23. Cristaudo A, Foddis R, Bonotti A, Simonini S, Vivaldi A, Guglielmi G, Ambrosino N, Canessa PA, Chella A, Lucchi M, Mussi A and Mutti L: Comparison between plasma and serum osteopontin levels: usefulness in diagnosis of epithelial malignant pleural mesothelioma. Int J Biol Markers 25: 164-170, 2010.
24. Sreekanthreddy P, Srinivasan H, Kumar DM, Nijaguna MB, Sridevi S, Vrinda M, Arivazhagan A, Balasubramaniam A, Hegde AS, Chandramouli BA, et al: Identification of potential serum biomarkers of glioblastoma: serum osteopontin levels correlate with poor prognosis. Cancer Epidemiol Biomarkers Prev 19: 1409-1422, 2010.
25. Isa S, Kawaguchi T, Teramukai S, Minato K, Ohsaki Y, Shibata K, Yonei T, Hayashibara K, Fukushima M, Kawahara M, Furuse K and Mack PC: Serum osteopontin levels are highly prognostic for survival in advanced non-small cell lung cancer: results from JMTO LC 0004. J Thorac Oncol 4: 1104-1110, 2009.